Shifamed spinout and intraocular lens maker Atia Vision announced today that it closed the second tranche of a $20 million Series D financing. Campbell, Calif.-based Atia Vision said in a news release that the funding round that was led by Cormorant Asset Management with participation from The Capital Partnership, AMED Ventures and Shangbay Capital. The […]
Newly formed Shifamed spinout Myra Medical said today that it closed a seed financing round worth $3.2 million and announced the appointment of Robert Chang as CEO. Campbell, Calif.-based Myra Medical was founded to produce surgical devices designed to enable maximum intraocular pressure reduction while reducing the risk of hypotony in patients with glaucoma. Proceeds […]
Atia Vision said today that it raised a $20 million Series D round for the intra-ocular lens it’s developing to treat far-sightedness. Campbell, Calif.-based Atia, which spun out of the Shifamed incubator there, said the round was led by Cormorant Asset Management and included the Capital Partnership, AMED Ventures and Shangbay Capital. Proceeds from the […]
Medtech incubator Shifamed portfolio company NuVera Medical said today it closed a $15 million financing round slated to support its real-time 3D intracardiac echocardiography technology platform. The round was led by Cormorant Asset Management and joined by the Capital Partnership, Lilly Asia Ventures and other existing shareholders, the Campbell, Calif.-based company said. “We are pleased to […]
Medtech incubator Shifamed said this week that its newly formed portfolio company Supira Medical has raised $15.5 million in a new round of financing. The round was led by The Capital Partnership and joined by Cormorant Asset Management and Shifamed Angels, the Campbell, Calif.-based incubator said. The round officially closed on April 25. Supira Medical […]
California startup Apama Medical raised $3.2 million in a Series A-1 financing round in support of a catheter-based technology that the company says is "vastly superior" in treatment of atrial fibrillation.
The company offered few details about the device in the press release or on its minimal website, but noted that it hopes to enter an atrial fibrillation mapping and ablation market that it expects to reach $2 billion by 2017.